https://www.businesswire.com/news/home/20180621006037/en/

NEWARK, Calif.--(BUSINESS WIRE)--Jun 21, 2018--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced initiation of patient dosing in the company’s ASPEN Phase 3 clinical program for its investigational drug candidate DaxibotulinumtoxinA for Injection (RT002) for the treatment of cervical dystonia (CD), a movement disorder of the neck.

“In our Phase 2 study, treatment with RT002 resulted in patients realizing clinically meaningful relief from the pain and disability associated with cervical dystonia for at least 24 weeks,” said Roman Rubio, MD, Senior Vice President of Clinical Development at Revance. “Current botulinum toxin injections for cervical dystonia are administered at approximately 12-week intervals. With the potential for twice yearly administration, RT002 could represent a meaningful advancement in treatment, providing significantly prolonged improvement of symptoms in patients.”